SOPHiA GENETICS SA (NASDAQ:SOPH) Given Average Rating of “Hold” by Brokerages

Shares of SOPHiA GENETICS SA (NASDAQ:SOPH) have been assigned a consensus rating of “Hold” from the five research firms that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $10.00.

A number of analysts recently commented on the company. HC Wainwright increased their price objective on SOPHiA GENETICS from $12.00 to $14.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. BTIG Research lifted their target price on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th.

Insiders Place Their Bets

In related news, Chairman Jurgi Camblong sold 8,500 shares of the stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $7.66, for a total value of $65,110.00. Following the completion of the transaction, the chairman owned 3,435,822 shares of the company’s stock, valued at approximately $26,318,396.52. This represents a 0.25% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Well Van sold 6,168 shares of the stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $7.63, for a total value of $47,061.84. Following the transaction, the insider owned 338,884 shares of the company’s stock, valued at approximately $2,585,684.92. This trade represents a 1.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 357,260 shares of company stock valued at $2,317,759. Company insiders own 4.88% of the company’s stock.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of institutional investors have recently modified their holdings of the company. First Dallas Securities Inc. bought a new position in SOPHiA GENETICS in the 1st quarter worth $50,000. Royal Bank of Canada raised its stake in SOPHiA GENETICS by 3,130.2% during the 1st quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after purchasing an additional 18,781 shares during the last quarter. AXQ Capital LP bought a new stake in SOPHiA GENETICS in the 2nd quarter valued at $119,000. Silverberg Bernstein Capital Management LLC boosted its holdings in SOPHiA GENETICS by 8.7% in the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 51,970 shares of the company’s stock valued at $257,000 after purchasing an additional 4,155 shares during the period. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in SOPHiA GENETICS in the 2nd quarter worth $567,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Price Performance

Shares of NASDAQ SOPH opened at $8.53 on Friday. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 0.58. The company’s 50-day moving average price is $7.23 and its 200 day moving average price is $5.79. SOPHiA GENETICS has a 52 week low of $3.15 and a 52 week high of $8.98. The stock has a market cap of $715.58 million, a price-to-earnings ratio of -7.42 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Wednesday, August 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%.The business had revenue of $23.31 million for the quarter, compared to analyst estimates of $21.72 million. As a group, research analysts forecast that SOPHiA GENETICS will post -0.77 earnings per share for the current fiscal year.

About SOPHiA GENETICS

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.